Perspectives and potential applications of nanomedicine in breast and prostate cancer

Medicinal Research Reviews

Volumn 33, Issue 1, 2013, Pages 3-32

  Liu, Yang ^a   Solomon, Metasebya ^a   Achilefu, Samuel ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Diagnostics; Imaging; Nanocarriers; Nanodevices; Personalized medicine; Therapeutics

Indexed keywords

CARBON NANOTUBE; CASPASE 3; DENDRIMER; GADOLINIUM; GOLD NANOPARTICLE; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 6; IRON OXIDE; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; NANOCARRIER; NANOMATERIAL; PENTETIC ACID; POLYMER; SUPERPARAMAGNETIC IRON OXIDE;

ARTICLE; BRACHYTHERAPY; BREAST CANCER; CANCER CELL; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER THERAPY; COMPUTER ASSISTED TOMOGRAPHY; DNA HYBRIDIZATION; DNA STRAND BREAKAGE; DRUG DELIVERY SYSTEM; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTERNAL BEAM RADIOTHERAPY; FLUORESCENCE; GENE DELETION; HUMAN; IONIZING RADIATION; MICELLE; MOLECULARLY TARGETED THERAPY; NANODEVICE; NANOMEDICINE; NEAR INFRARED SPECTROSCOPY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PERSONALIZED MEDICINE; PHOTODYNAMIC THERAPY; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; PROTEIN EXPRESSION; SAFETY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANIMALS; BREAST NEOPLASMS; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; MALE; NANOMEDICINE; NANOSTRUCTURES; PROSTATIC NEOPLASMS;

EID: 79955160470     PISSN: 01986325     EISSN: 10981128     Source Type: Journal    
DOI: 10.1002/med.20233     Document Type: Article

References (230)

1. [Anonymous] Review of the federal strategy for nanotechnology-related environmental, health, and safety research. Res Technol Manage 2009;52:62-63.
2. Jain KK. Nanomedicine: Application of nanobiotechnology in medical practice. Med Princ Pract 2008;17:89-101.
3. Liu Y, Ramanath HS, Wang DA. Tendon tissue engineering using scaffold enhancing strategies. Trends Biotechnol 2008;26:201-209.
4. Nakayama Y, Pauzauskie PJ, Radenovic A, Onorato RM, Saykally RJ, Liphardt J, Yang P. Tunable nanowire nonlinear optical probe. Nature 2007;447:U1098.
5. Ouyang M, Huang JL, Lieber CM. One-dimensional energy dispersion of single-walled carbon nanotubes by resonant electron scattering. Phys Rev Lett 2002;88:066804.
6. Moghimi SM, Hunter AC, Murray JC. Nanomedicine: Current status and future prospects. FASEB J 2005;19:311-330.
7. Smith RA, Cokkinides V, Brawley OW. Cancer screening in the United States, 2009: A review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin 2009;59:27-41.
8. Almutairi A, Akers WJ, Berezin MY, Achilefu S, Frechet JM. Monitoring the biodegradation of dendritic near-infrared nanoprobes by in vivo fluorescence imaging. Mol Pharm 2008;5:1103-1110.
9. Almutairi A, Guillaudeu SJ, Berezin MY, Achilefu S, Frechet JM. Biodegradable pH-sensing dendritic nanoprobes for near-infrared fluorescence lifetime and intensity imaging. J Am Chem Soc 2008;130:444-445.
10. Kim S, Ohulchanskyy TY, Pudavar HE, Pandey RK, Prasad PN. Organically modified silica nanoparticles co-encapsulating photosensitizing drug and aggregation-enhanced two-photon absorbing fluorescent dye aggregates for two-photon photodynamic therapy. J Am Chem Soc 2007;129:2669-2675.
11. Reddy GR, Bhojan MS, McConville P, Moody J, Moffat BA, Hall DE, Kim G, Koo YEL, Woolliscroft MJ, Sugai JV, Johnson TD, Philbert MA, Kopelman R, Rehemtulla A, Ross BD. Vascular targeted nanoparticles for imaging and treatment of brain tumors. Clin Cancer Res 2006;12:6677-6686.
12. Caruthers SD, Wickline SA, Lanza GM. Nanotechnological applications in medicine. Curr Opin Biotechnol 2007;18:26-30.
13. Hecht S, Frechet JM. Dendritic encapsulation of function: Applying nature's site isolation principle from biomimetics to materials science. Angew Chem Int Ed Engl 2001;40:74-91.
14. Liu MJ, Frechet JMJ. Designing dendrimers for drug delivery. Pharm Sci Technol Today 1999;2:393-401.
15. Tomalia DA, Baker H, Dewald J, Hall M, Kallos G, Martin S, Roeck J, Ryder J, Smith P. A new class of polymers-Starburst-dendritic macromolecules. Polym J 1985;17:117-132.
16. Hawker CJ, Frechet JMJ. Preparation of polymers with controlled molecular architecture-A new convergent approach to dendritic macromolecules. J Am Chem Soc 1990;112:7638-7647.
17. Lee CC, MacKay JA, Frechet JM, Szoka FC. Designing dendrimers for biological applications. Nat Biotechnol 2005;23:1517-1526.
18. Bogdanov AA, Callahan RJ, Wilkinson RA, Martin C, Cameron JA, Fischman AJ, Brady TJ, Weissleder R. Synthetic copolymer kit for radionuclide blood-pool imaging. J Nucl Med 1994;35:1880-1886.
19. Bogdanov AA, Martin C, Bogdanova AV, Brady TJ, Weissleder R. An adduct of cis-diamminedichloroplatinum (II) and poly(ethylene glycol)poly(L-lysine)-succinate: Synthesis and cytotoxic properties. Bioconjug Chem 1996;7:144-149.
20. Bogdanov AA, Weissleder R, Frank HW, Bogdanova AV, Nossif N, Schaffer BK, Tsai E, Papisov MI, Brady TJ. A new macromolecule as a contrast agent for Mr-angiography-Preparation, properties, and animal studies. Radiology 1993;187:701-706.
21. Weissleder R, Wang YM, Papisov M, Bogdanov A, Schaffer B, Brady TJ, Wittenberg J. Polymeric contrast agents for Mr imaging of adrenal-glands. J Magn Reson Im 1993;3:93-97.
22. Bremer C, Tung CH, Weissleder R. In vivo molecular target assessment of matrix metalloproteinase inhibition. Nat Med 2001;7:743-748.
23. Mahmood U, Tung CH, Bogdanov A, Weissleder R. Near-infrared optical imaging of protease activity for tumor detection. Radiology 1999;213:866-870.
24. Tung CH, Mahmood U, Bredow S, Weissleder R. In vivo imaging of proteolytic enzyme activity using a novel molecular reporter. Cancer Res 2000;60:4953-4958.
25. Weissleder R, Tung CH, Mahmood U, Bogdanov A. In vivo imaging of tumors with protease-activated near-infrared fluorescent probes. Nat Biotechnol 1999;17:375-378.
26. Jones MC, Leroux JC. Polymeric micelles-A new generation of colloidal drug carriers. Eur J Pharm Biopharm 1999;48:101-111.
27. Bae Y, Kataoka K. Intelligent polymeric micelles from functional poly(ethylene glycol)-poly(amino acid) block copolymers. Adv Drug Deliv Rev 2009;61:768-784.
28. Osada K, Christie RJ, Kataoka K. Polymeric micelles from poly(ethylene glycol)-poly(amino acid) block copolymer for drug and gene delivery. J R Soc Interface 2009;6:S325-S339.
29. Jesorka A, Orwar O. Liposomes: Technologies and analytical applications. Annu Rev Anal Chem 2008;1:801-832.
30. Karanth H, Murthy RSR. pH-sensitive liposomes-Principle and application in cancer therapy. J Pharm Pharmacol 2007;59:469-483.
31. Tran MA, Watts RJ, Robertson GP. Use of liposomes as drug delivery vehicles for treatment of melanoma. Pigm Cell Melan Res 2009;22:388-399.
32. Hezinger AFE, Tessmar J, Gopferich A. Polymer coating of quantum dots-A powerful tool toward diagnostics and sensorics. Eur J Pharm Biopharm 2008;68:138-152.
33. Xing Y, Xia ZY, Rao JH. Semiconductor quantum dots for biosensing and in vivo imaging. IEEE Trans Nanobiosci 2009;8:4-12.
34. van Driel AF, Allan G, Delerue C, Lodahl P, Vos WL, Vanmaekelbergh D. Frequency-dependent spontaneous emission rate from CdSe and CdTe nanocrystals: Influence of dark states. Phys Rev Lett 2005;95:236804.
35. Qi LF, Gao XH. Emerging application of quantum dots for drug delivery and therapy. Expert Opin Drug Del 2008;5:263-267.
36. Dai HJ. Nanotube growth and characterization. Top Appl Phys 2001;80:29-53.
37. Hong H, Gao T, Cai WB. Molecular imaging with single-walled carbon nanotubes. Nano Today 2009;4:252-261.
38. Saito N, Usui Y, Aoki K, Narita N, Shimizu M, Hara K, Ogiwara N, Nakamura K, Ishigaki N, Kato H, Taruta S, Endo M. Carbon nanotubes: Biomaterial applications. Chem Soc Rev 2009;38:1897-1903.
39. Ding L, Stilwell J, Zhang T, Elboudwarej O, Jiang H, Selegue JP, Cooke PA, Gray JW, Chen FF. Molecular characterization of the cytotoxic mechanism of multiwall carbon nanotubes and nano-onions on human skin fibroblast. Nano Lett 2005;5:2448-2464.
40. Jia G, Wang H, Yan L, Wang X, Pei R, Yan T, Zhao Y, Guo X. Cytotoxicity of carbon nanomaterials: Single-wall nanotube, multi-wall nanotube, and fullerene. Environ Sci Technol 2005;39:1378-1383.
41. Manna SK, Sarkar S, Barr J, Wise K, Barrera EV, Jejelowo O, Rice-Ficht AC, Ramesh GT. Single-walled carbon nanotube induces oxidative stress and activates nuclear transcription factor-kappa B in human keratinocytes. Nano Lett 2005;5:1676-1684.
42. Shvedova AA, Castranova V, Kisin ER, Schwegler-Berry D, Murray AR, Gandelsman VZ, Maynard A, Baron P. Exposure to carbon nanotube material: Assessment of nanotube cytotoxicity using human keratinocyte cells. J Toxicol Env Heal A 2003;66:1909-1926.
43. Yong KT, Swihart MT, Ding H, Prasad PN. Preparation of gold nanoparticles and their applications in anisotropic nanoparticle synthesis and bioimaging. Plasmonics 2009;4:79-93.
44. Huang XH, Jain PK, El-Sayed IH, El-Sayed MA. Plasmonic photothermal therapy (PPTT) using gold nanoparticles. Laser Med Sci 2008;23:217-228.
45. Panyala NR, Pena-Mendez EM, Havel J. Gold and nano-gold in medicine: Overview, toxicology and perspectives. J Appl Biomed 2009;7:75-91.
46. Kaufmann SH, Earnshaw WC. Induction of apoptosis by cancer chemotherapy. Exp Cell Res 2000;256:42-49.
47. Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S, Manikhas G, Makhson A, Roth A, Dodwell D, Baselga J, Biakhov M, Valuckas K, Voznyi E, Liu X, Vercammen E. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: A survival study. J Clin Oncol 2005;23:5960-5972.
48. Pommier Y, Sordet O, Antony S, Hayward RL, Kohn KW. Apoptosis defects and chemotherapy resistance: Molecular interaction maps and networks. Oncogene 2004;23:2934-2949.
49. Iyer AK, Khaled G, Fang J, Maeda H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today 2006;11:812-818.
50. Tanaka T, Shiramoto S, Miyashita M, Fujishima Y, Kaneo Y. Tumor targeting based on the effect of enhanced permeability and retention (EPR) and the mechanism of receptor-mediated endocytosis (RME). Int J Pharm 2004;277:39-61.
51. Greish K. Enhanced permeability and retention of macromolecular drugs in solid tumors: A royal gate for targeted anticancer nanomedicines. J Drug Target 2007;15:457-464.
52. Qian ZM, Li HY, Sun HZ, Ho K. Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol Rev 2002;54:561-587.
53. Sun C, Sze R, Zhang MQ. Folic acid-PEG conjugated superparamagnetic nanoparticles for targeted cellular uptake and detection by MRI. J Biomed Mater Res A 2006;78A:550-557.
54. Bloch S, Xu B, Ye Y, Liang K, Nikiforovich GV, Achilefu S. Targeting beta-3 integrin using a linear hexapeptide labeled with a near-infrared fluorescent molecular probe. Mol Pharm 2006;3:539-557.
55. Edwards WB, Akers WJ, Ye Y, Cheney PP, Bloch S, Xu B, Laforest R, Achilefu S. Multimodal imaging of integrin receptor-positive tumors by bioluminescence, fluorescence, gamma scintigraphy, and single-photon emission computed tomography using a cyclic RGD peptide labeled with a near-infrared fluorescent dye and a radionuclide. Mol Imaging 2009;8:101-110.
56. Ye Y, Bloch S, Xu B, Achilefu S. Novel near-infrared fluorescent integrin-targeted DFO analogue. Bioconjug Chem 2008;19:225-234.
57. Sprague JE, Li WP, Liang KX, Achilefu S, Anderson CJ. In vitro and in vivo investigation of matrix metalloproteinase expression in metastatic tumor models. Nucl Med Biol 2006;33:227-237.
58. Pu Y, Wang WB, Das BB, Achilefu S, Alfano RR. Time-resolved fluorescence polarization dynamics and optical imaging of cytate: A prostate cancer receptor-targeted contrast agent. Appl Opt 2008;47:2281-2289.
59. Odonkor CA, Achilefu S. Modulation of effector caspase cleavage determines response of breast and lung tumor cell lines to chemotherapy. Cancer Invest 2009;27:417-429.
60. Bugaj JE, Achilefu S, Dorshow RB, Rajagopalan R. Novel fluorescent contrast agents for optical imaging of in vivo tumors based on a receptor-targeted dye-peptide conjugate platform. J Biomed Opt 2001;6:122-133.
61. Hoffman TJ, Gali H, Smith CJ, Sieckman GL, Hayes DL, Owen NK, Volkert WA. Novel series of In-111-labeled bombesin analogs as potential radiopharmaceuticals for specific targeting of gastrin-releasing peptide receptors expressed on human prostate cancer cells. J Nucl Med 2003;44:823-831.
62. Nock B, Nikolopoulou A, Chiotellis E, Loudos G, Maintas D, Reubi JC, Maina T. [Tc-99m]Demobesin 1, a novel potent bombesin analogue for GRP receptor-targeted tumour imaging. Eur J Nucl Med Mol I 2003;30;247-258.
63. Okarvi SM, Al-Jammaz I. Synthesis, radiolabelling and biological characteristics of a bombesin peptide analog as a tumor imaging agent. Anticancer Res 2003;23:2745-2750.
64. Scopinaro F, De Vincentis G, Varvarigou AD, Laurenti C, Iori F, Remediani S, Chiarini S, Stella S. Tc-99m-bombesin detects prostate cancer and invasion of pelvic lymph nodes. Eur J Nucl Med Mol I 2003;30:1378-1382.
65. Sun BD, Halmos G, Schally AV, Wang XF, Martinez M. Presence of receptors for bombesin/gastrin-releasing peptide and mRNA for three receptor subtypes in human prostate cancers. Prostate 2000;42:295-303.
66. Van de Wiele C, Dumont F, Vanden Broecke R, Oosterlinck W, Cocquyt V, Serreyn R, Peers S, Thornback J, Slegers G, Dierckx RA. Technetium-99m RP527, a GRP analogue for visualisation of GRP receptor-expressing malignancies: A feasibility study. Eur J Nucl Med 2000;27:1694-1699.
67. Eiblmaier M, Meyer LA, Watson MA, Fracasso PM, Pike LJ, Anderson CJ. Correlating EGFR expression with receptor-binding properties and internalization of Cu-64-DOTA-cetuximab in 5 cervical cancer cell lines. J Nucl Med 2008;49:1472-1479.
68. Li WP, Meyer LA, Capretto DA, Sherman CD, Anderson CJ. Receptor-binding, biodistribution, and metabolism studies of Cu-64-DOTA-cetuximab, a PET-imaging agent for epidermal growth-factor receptor-positive tumors. Cancer Biother Radio 2008;23:158-171.
69. Mishani E, Abourbeh G, Eiblmaier M, Anderson CJ. Imaging of EGFR and EGFR tyrosine kinase overexpression in tumors by nuclear medicine modalities. Curr Pharm Des 2008;14:2983-2998.
70. Li JL, Wang L, Liu XY, Zhang ZP, Guo HC, Liu WM, Tang SH. In vitro cancer cell imaging and therapy using transferrin-conjugated gold nanoparticles. Cancer Lett 2009;274:319-326.
71. Sahoo SK, Ma W, Labhasetwar V. Efficacy of transferrin-conjugated paclitaxel-loaded nanoparticles in a murine model of prostate cancer. Int J Cancer 2004;112:335-340.
72. Pan J, Feng SS. Targeted delivery of paclitaxel using folate-decorated poly(lactide)-Vitamin E TPGS nanoparticles. Biomaterials 2008;29:2663-2672.
73. Sonvico F, Mornet S, Vasseur S, Dubernet C, Jaillard D, Degrouard J, Hoebeke J, Duguet E, Colombo P, Couvreur P. Folate-conjugated iron oxide nanoparticles for solid tumor targeting as potential specific magnetic hyperthermia mediators: Synthesis, physicochemical characterization, and in vitro experiments. Bioconjug Chem 2005;16:1181-1188.
74. Lee S, Cha EJ, Park K, Lee SY, Hong JK, Sun IC, Kim SY, Choi K, Kwon IC, Kim K, Ahn CH. A near-infrared-fluorescence-quenched gold-nanoparticle imaging probe for in vivo drug screening and protease activity determination. Angew Chem Int Ed 2008;47:2804-2807.
75. Chatzistamou I, Schally AV, Nagy A, Armatis P, Szepeshazi K, Halmos G. Effective treatment of metastatic MDA-MB-435 human estrogen-independent breast carcinomas with a targeted cytotoxic analogue of luteinizing hormone-releasing hormone AN-207. Clin Cancer Res 2000;6:4158-4165.
76. Lojun S, Bao S, Lei ZM, Rao CV. Presence of functional luteinizing hormone/chorionic gonadotropin (hCG) receptors in human breast cell lines: Implications supporting the premise that hCG protects women against breast cancer. Biol Reprod 1997;57:1202-1210.
77. Duggan C, Maguire T, McDermott E, O'Higgins N, Fennelly JJ, Duffy MJ. Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer. Int J Cancer 1995;61:597-600.
78. Han B, Nakamura M, Mori I, Nakamura Y, Kakudo K. Urokinase-type plasminogen activator system and breast cancer (review). Oncol Rep 2005;14:105-112.
79. Dagar S, Sekosan M, Rubinstein I, Onyuksel H. Detection of VIP receptors in MNU-induced breast cancer in rats: Implications for breast cancer targeting. Breast Cancer Res Treat 2001;65:49-54.
80. Dagar S, Sekosan M, Lee BS, Rubinstein I, Onyuksel H. VIP receptors as molecular targets of breast cancer: Implications for targeted imaging and drug delivery. J Control Release 2001;74:129-134.
81. Dagar S, Krishnadas A, Rubinstein I, Blend MJ, Onyuksel H. VIP grafted sterically stabilized liposomes for targeted imaging of breast cancer: In vivo studies. J Control Release 2003;91:123-133.
82. Patolsky F, Zheng G, Lieber CM. Nanowire-based biosensors. Anal Chem 2006;78:4260-4269.
83. Zheng G, Patolsky F, Cui Y, Wang WU, Lieber CM. Multiplexed electrical detection of cancer markers with nanowire sensor arrays. Nat Biotechnol 2005;23:1294-1301.
84. Chen CP, Ganguly A, Wang CH, Hsu CW, Chattopadhyay S, Hsu YK, Chang YC, Chen KH, Chen LC. Label-free dual sensing of DNA molecules using GaN nanowires. Anal Chem 2009;81:36-42.
85. 3 nanowires and carbon nanotubes. J Am Chem Soc 2005;127:12484-12485.
86. Kim JP, Lee BY, Lee J, Hong S, Sim SJ. Enhancement of sensitivity and specificity by surface modification of carbon nanotubes in diagnosis of prostate cancer based on carbon nanotube field effect transistors. Biosens Bioelectron 2009;24:3372-3378.
87. Shao N, Wickstrom E, Panchapakesan B. Nanotube-antibody biosensor arrays for the detection of circulating breast cancer cells. Nanotechnology 2008;19:465101.
88. Yu X, Munge B, Patel V, Jensen G, Bhirde A, Gong JD, Kim SN, Gillespie J, Gutkind JS, Papadimitrakopoulos F, Rusling JF. Carbon nanotube amplification strategies for highly sensitive immunodetection of cancer biomarkers. J Am Chem Soc 2006;128:11199-11205.
89. Wang J, Kawde AN, Jan MR. Carbon-nanotube-modified electrodes for amplified enzyme-based electrical detection of DNA hybridization. Biosens Bioelectron 2004;20:995-1000.
90. Okuno J, Maehashi K, Kerman K, Takamura Y, Matsumoto K, Tamiya E. Label-free immunosensor for prostate-specific antigen based on single-walled carbon nanotube array-modified microelectrodes. Biosens Bioelectron 2007;22:2377-2381.
91. Tsujita Y, Maehashi K, Matsumoto K, Chikae M, Takamura Y, Tamiya E. Microfluidic and label-free multi-immunosensors based on carbon nanotube microelectrodes. Jpn J Appl Phys 2009;48:06FJ02.
92. Gokarna A, Jin LH, Hwang JS, Cho YH, Lim YT, Chung BH, Youn SH, Choi DS, Lim JH. Quantum dot-based protein micro- and nanoarrays for detection of prostate cancer biomarkers. Proteomics 2008;8:1809-1818.
93. Zajac A, Song DS, Qian W, Zhukov T. Protein microarrays and quantum dot probes for early cancer detection. Colloid Surface B 2007;58:309-314.
94. Jokerst JV, Raamanathan A, Christodoulides N, Floriano PN, Pollard AA, Simmons GW, Wong J, Gage C, Furmaga WB, Redding SW, McDevitt JT. Nano-bio-chips for high performance multiplexed protein detection: Determinations of cancer biomarkers in serum and saliva using quantum dot bioconjugate labels. Biosens Bioelectron 2009;24:3622-3629.
95. Fu YZ, Yaan R, Chai YQ, Zhang Y, Peng YG. Electrochemical immunoanalysis for carcinoembryonic antigen based on multilayer architectures of gold nanoparticles and polycation biomimetic interface on glassy carbon electrode. Electroanal 2006;18:2451-2457.
96. Zhang TT, Yuan R, Chai YQ, Liu KG, Ling SJ. Study on an immunosensor based on gold nanoparticles and a nano-calcium carbonate/Prussian blue modified glassy carbon electrode. Microchim Acta 2009;165:53-58.
97. Lin JH, Qu W, Zhang SS. Electrochemical immunosensor for carcinoembryonic antigen based on antigen immobilization in gold nanoparticles modified chitosan membrane. Anal Sci 2007;23:1059-1063.
98. DeMartini W, Lehman C, Partridge S. Breast MRI for cancer detection and characterization: A review of evidence-based clinical applications. Acad Radiol 2008;15:408-416.
99. Gu P, Pan LL, Wu SQ, Sun L, Huang G. CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma A systematic review and meta-analysis. Eur J Radiol 2009;71:164-174.
100. Houssami N, Hayes DF. Review of preoperative magnetic resonance imaging (MRI) in breast cancer should MRI be performed on all women with newly diagnosed, early stage breast cancer? CA Cancer J Clin 2009;59:290-302.
101. Lord SJ, Lei W, Craft P, Cawson JN, Morris I, Walleser S, Griffiths A, Parker S, Houssami N. A systematic review of the effectiveness of magnetic resonance imaging (MRI) as an addition to mammography and ultrasound in screening young women at high risk of breast cancer. Eur J Cancer 2007;43:1905-1917.
102. Mann RM, Hoogeveen YL, Blickman JG, Boetes C. MRI compared to conventional diagnostic work-up in the detection and evaluation of invasive lobular carcinoma of the breast: A review of existing literature. Breast Cancer Res Tr 2008;107:1-14.
103. Rausch DR. Spectrum of extra-mammary findings on breast MRI: A pictorial review. Breast J 2008;14:592-594.
104. Hellwig D, Baum RP, Kirsch C. FDG-PET, PET/CT and conventional nuclear medicine procedures in the evaluation of lung cancer: A systematic review. Nuklearmedizin 2009;48:59-69.
105. Kwee TC, Kwee RM. Combined FDG-PET/CT for the detection of unknown primary tumors: Systematic review and meta-analysis. Eur Radiol 2009;19:731-744.
106. Krug B, Crott R, Lonneux M, Baurain JF, Pirson AS, Borght TV. Role of PET in the initial staging of cutaneous malignant melanoma: Systematic review. Radiology 2008;249:836-844.
107. Mac Manus M, Hicks RJ. The use of positron emission tomography (Pet) in the staging/evaluation, treatment, and follow-up of patients with lung cancer: A critical review. Int J Radiat Oncol 2008;72:1298-1306.
108. Douis H, Jafri M. Added value of PET and PET-computed tomography in oesophageal cancer: A review of current practice. Nucl Med Commun 2008;29:840.
109. Brady Z, Taylor ML, Haynes M, Whitaker M, Mullen A, Clews L, Partridge M, Hicks RJ, Trapp JV. The clinical application of PET/CT: A contemporary review. Australas Phys Eng Sci Med 2008;31:90-109.
110. Sloka JS, Hollett PD, Mathews M. A quantitative review of the use of FDG-PET in the axillary staging of breast cancer. Med Sci Monit 2007;13:Ra37-Ra46.
111. Senan S, De Ruysscher D. Critical review of PET-CT for radiotherapy planning in lung cancer. Crit Rev Oncol Hemat 2005;56:345-351.
112. Kubota K. From tumor biology to clinical PET: A review of positron emission tomography (PET) in oncology. Ann Nucl Med 2001;15:471-486.
113. Achilefu S. Lighting up tumors with receptor-specific optical molecular probes. Technol Cancer Res T 2004;3:393-409.
114. Koehl GE, Gaumann A, Geissler EK. Intravital microscopy of tumor angiogenesis and regression in the dorsal skin fold chamber: Mechanistic insights and preclinical testing of therapeutic strategies. Clin Exp Metastasis 2009;26:329-344.
115. Niesner RA, Andresen V, Gunzer M. Intravital two-photon microscopy: Focus on speed and time resolved imaging modalities. Immunol Rev 2008;221:7-25.
116. Croix CMS, Leelavanichkul K, Watkins SC. Intravital fluorescence microscopy in pulmonary research. Adv Drug Deliv Rev 2006;58:834-840.
117. Norman K. Techniques: Intravital microscopy-A method for investigating disseminated intravascular coagulation? Trends Pharmacol Sci 2005;26:327-332.
118. Molitoris BA, Sandoval RM. Intravital multiphoton microscopy of dynamic renal processes. Am J Physiol Renal 2005;288:F1084-F1089.
119. Sumen C, Mempel TR, Mazo IB, von Andrian UH. Intravital microscopy: Visualizing immunity in context. Immunity 2004;21:315-329.
120. Fujimoto JG, Pitris C, Boppart SA, Brezinski ME. Optical coherence tomography: An emerging technology for biomedical imaging and optical biopsy. Neoplasia 2000;2:9-25.
121. Schmitt JM. Optical coherence tomography (OCT): A review. IEEE J Sel Top Quant 1999;5:1205-1215.
122. Cucu RG, Podoleanu AG, Rogers JA, Pedro J, Rosen RB. Combined confocal/en face T-scan-based ultrahigh-resolution optical coherence tomography in vivo retinal imaging. Opt Lett 2006;31:1684-1686.
123. Hsiung PL, Pantanowitz L, Aguirre AD, Chen Y, Phatak D, Ko TH, Bourquin S, Schnitt SJ, Raza S, Connolly JL, Mashimo H, Fujimoto JG. Ultrahigh-resolution and 3-dimensional optical coherence tomography ex vivo imaging of the large and small intestines. Gastrointest Endosc 2005;62:561-574.
124. Grieve K, Moneron G, Dubois A, Le Gargasson JF, Boccara C. Ultrahigh resolution ex vivo ocular imaging using ultrashort acquisition time en face optical coherence tomography. J Opt A Pure Appl Opt 2005;7:368-373.
125. Bizheva K, Unterhuber A, Hermann B, Povazay B, Sattmann H, Drexler W, Stingl A, Le T, Mei M, Holzwarth R, Reitsamer HA, Morgan JE, Cowey A. Imaging ex vivo and in vitro brain morphology in animal models with ultrahigh resolution optical coherence tomography. J Biomed Opt 2004;9:719-724.
126. Fujimoto JG. Optical coherence tomography for ultrahigh resolution in vivo imaging. Nat Biotechnol 2003;21:1361-1367.
127. Ghanta NK, Drexler W, Morgner U, Ko T, Kartner FX, Clermont A, Bursell SE, Fujimoto JG. In vivo ultrahigh resolution spectroscopic optical coherence tomography for imaging transgenic mice models. Invest Ophthalmol Vis Sci 2000;41:S173.
128. Brezinski ME, Tearney GJ, Boppart SA, Bouma BE, Pitris C, Southern JF, Fujimoto JG. Ultrahigh resolution catheter based in vivo imaging of the rabbit aorta with optical coherence tomography. Circulation 1997;96:3294.
129. Axelsson J, Swartling J, Andersson-Engels S. In vivo photosensitizer tomography inside the human prostate. Opt Lett 2009:34:232-234.
130. Wang KKH, Zhu TC. Reconstruction of in-vivo optical properties for human prostate using interstitial diffuse optical tomography. Op Express 2009:17:11665-11672.
131. Achilefu S. Biophotonics-Unravelling animal anatomy. Nat Photonics 2007;1:496-497.
132. Bloch S, Lesage F, McIntosh L, Gandjbakhche A, Liang KX, Achilefu S. Whole-body fluorescence lifetime imaging of a tumor-targeted near-infrared molecular probe in mice. J Biomed Opt 2005;10:054003.
133. Hillman EMC, Moore A. All-optical anatomical co-registration for molecular imaging of small animals using dynamic contrast. Nat Photonics 2007;1:526-530.
134. Patwardhan SV, Bloch SR, Achilefu S, Culver JP. Time-dependent whole-body fluorescence tomography of probe bio-distributions in mice. Opt Express 2005;13:2564-2577.
135. Nothdurft RE, Patwardhan SV, Akers W, Ye YP, Achilefu S, Culver JP. In vivo fluorescence lifetime tomography. J Biomed Opt 2009;14:024004.
136. Kumar ATN, Raymond SB, Dunn AK, Bacskai BJ, Boas DA. A time domain fluorescence tomography system for small animal imaging. IEEE T Med Imaging 2008;27:1152-1163.
137. Akers W, Lesage F, Holten D, Achilefu S. In vivo resolution of multiexponential decays of multiple near-infrared molecular probes by fluorescence lifetime-gated whole-body time-resolved diffuse optical imaging. Mol Imaging 2007;6:237-246.
138. Achilefu S, Dorshow RB, Bugaj JE, Rajagopalan R. Novel receptor-targeted fluorescent contrast agents for in vivo tumor imaging. Invest Radiol 2000;35:479-485.
139. Berlier JE, Rothe A, Buller G, Bradford J, Gray DR, Filanoski BJ, Telford WG, Yue S, Liu JX, Cheung CY, Chang W, Hirsch JD, Beechem JM, Haugland RP, Haugland RP. Quantitative comparison of long-wavelength Alexa Fluor dyes to Cy dyes: Fluorescence of the dyes and their bioconjugates. J Histochem Cytochem 2003;51:1699-1712.
140. Lee H, Mason JC, Achilefu S. Heptamethine cyanine dyes with a robust C-C bond at the central position of the chromophore. J Org Chem 2006;71:7862-7865.
141. Lin YH, Weissleder R, Tung CH. Novel near-infrared cyanine fluorochromes: Synthesis, properties, and bioconjugation. Bioconjug Chem 2002;13:605-610.
142. Oishi M, Tamura A, Nakamura T, Nagasaki Y. A smart nanoprobe based on fluorescence-quenching PEGylated nanogels containing gold nanoparticles for monitoring the response to cancer therapy. Adv Funct Mater 2009;19:827-834.
143. Gao XH, Cui YY, Levenson RM, Chung LWK, Nie SM. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol 2004;22:969-976.
144. Welsher K, Liu Z, Sherlock S, Robinson JT, Chen Z, Daranciang D, Dai H. A route to brightly fluorescent carbon nanotubes for near-infrared imaging in mice. Nat Nanotechnol 2009.
145. Van de Wiele C, Lahorte C, Oyen W, Boerman O, Goethals I, Slegers G, Dierckx RA. Nuclear medicine imaging to predict response to radiotherapy: A review. Int J Radiat Oncol Biol Phys 2003;55:5-15.
146. Berghammer P, Obwegeser R, Sinzinger H. Nuclear medicine and breast cancer: A review of current strategies and novel therapies. Breast 2001;10:184-197.
147. Martinez MJ, Ziegler SI, Beyer T. PET and PET/CT: Basic principles and instrumentation. Recent Results Cancer Res 2008;170:1-23.
148. Patton JA, Turkington TG. SPECT/CT physical principles and attenuation correction. J Nucl Med Technol 2008;36:1-10.
149. Maurer AH. Combined imaging modalities: PET/CT and SPECT/CT. Health Phys 2008;95:571-576.
150. Nunez EGF, Faintuch BL, Teodoro R, Wiecek DP, Martinelli JR, da Silva NG, Castanheira CE, de Oliveira RS, Pasqualini R. Influence of colloid particle profile on sentinel lymph node uptake. Nucl Med Biol 2009;36:741-747.
151. Jimenez IR, Roca M, Vega E, Garcia ML, Benitez A, Bajen M, Martin-Comin J. Particle sizes of colloids to be used in sentinel lymph node radiolocalization. Nucl Med Commun 2008;29:166-172.
152. 64Cu-labeled folate-conjugated shell cross-linked nanoparticles for tumor imaging and radiotherapy: Synthesis, radiolabeling, and biologic evaluation. J Nucl Med 2005;46:1210-1218.
153. Liu Z, Cai W, He L, Nakayama N, Chen K, Sun X, Chen X, Dai H. In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. Nat Nanotechnol 2007;2:47-52.
154. Kobayashi H, Sato N, Saga T, Nakamoto Y, Ishimori T, Toyama S, Togashi K, Konishi J, Brechbiel MW. Monoclonal antibody-dendrimer conjugates enable radiolabeling of antibody with markedly high specific activity with minimal loss of immunoreactivity. Eur J Nucl Med 2000;27:1334-1339.
155. Bangard C, Krug B, Lackner KJ. Monitoring of treatment response with CT and MRI: Basic principles. Onkologe 2009;15:457.
156. Bernada P, Stenstrom S, Mansson S. Experimental study of the moisture distribution inside a pulp sheet using MRI. Part I: Principles of the MRI technique. J Pulp Pap Sci 1998;24:373-379.
157. Sharma HA. MRI physics-basic principles. Acta Neuropsychiatr 2009;21:200-201.
158. Niendorf HP, Dinger JC, Haustein J, Cornelius I, Alhassan A, Clauss W. Tolerance data of Gd-DTPA: A review. Eur J Radiol 1991;13:15-20.
159. Runge VM, Carollo BR, Wolf CR, Nelson KL, Gelblum DY. Gd DTPA: A review of clinical indications in central nervous system magnetic resonance imaging. Radiographics 1989;9:929-958.
160. Shubayev VI, Pisanic TR, Jin SH. Magnetic nanoparticles for theragnostics. Adv Drug Deliv Rev 2009:61:467-477.
161. Waters EA, Wickline SA. Contrast agents for MRI. Basic Res Cardiol 2008;103:114-121.
162. Chen TJ, Cheng TH, Chen CY, Hsu SC, Cheng TL, Liu GC, Wang YM. Targeted herceptin-dextran iron oxide nanoparticles for noninvasive imaging of HER2/neu receptors using MRI. J Biol Inorg Chem 2009;14:253-260.
163. Leuschner C, Kumar CS, Hansel W, Soboyejo W, Zhou J, Hormes J. LHRH-conjugated magnetic iron oxide nanoparticles for detection of breast cancer metastases. Breast Cancer Res Treat 2006;99:163-176.
164. Lee JH, Huh YM, Jun YW, Seo JW, Jang JT, Song HT, Kim S, Cho EJ, Yoon HG, Suh JS, Cheon J. Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging. Nat Med 2007;13:95-99.
165. Rodriguez O, Fricke S, Chien C, Dettin L, VanMeter J, Shapiro E, Dai HN, Casimiro M, Ileva L, Dagata J, Johnson MD, Lisanti MP, Koretsky A, Albanese C. Contrast-enhanced in vivo imaging of breast and prostate cancer cells by MRI. Cell Cycle 2006;5:113-119.
166. Yang XQ, Pilla S, Grailer JJ, Steeber DA, Gong SQ, Chen YH, Chen GH. Tumor-targeting, superparamagnetic polymeric vesicles as highly efficient MRI contrast probes. J Mater Chem 2009;19:5812-5817.
167. Culver J, Akers W, Achilefu S. Multimodality molecular imaging with combined optical and SPECT/PET modalities. J Nucl Med 2008;49:169-172.
168. Kircher MF, Mahmood U, King RS, Weissleder R, Josephson L. A multimodal nanoparticle for preoperative magnetic resonance imaging and intraoperative optical brain tumor delineation. Cancer Res 2003;63:8122-8125.
169. Yang LL, Peng XH, Wang YA, Wang XX, Cao ZH, Ni CC, Karna P, Zhang XJ, Wood WC, Gao XH, Nie SM, Mao H. Receptor-targeted nanoparticles for in vivo imaging of breast cancer. Clini Cancer Res 2009;15:4722-4732.
170. Lee HY, Li Z, Chen K, Hsu AR, Xu CJ, Xie J, Sun SH, Chen XY. PET/MRI dual-modality tumor imaging using arginine-glycine-aspartic (RGD)-Conjugated radiolabeled iron oxide nanoparticles. J Nucl Med 2008;49:1371-1379.
171. Houston JP, Ke S, Wang W, Li C, Sevick-Muraca EM. Quality analysis of in vivo near-infrared fluorescence and conventional gamma images acquired using a dual-labeled tumor-targeting probe. J Biomed Opt 2005;10:054010.
172. Lee H, Akers WJ, Cheney PP, Edwards WB, Liang KX, Culver JP, Achilefu S. Complementary optical and nuclear imaging of caspase-3 activity using combined activatable and radio-labeled multimodality molecular probe. J Biomed Opt 2009;14:040507.
173. Wang W, Ke S, Kwon S, Yallampalli S, Cameron AG, Adams KE, Mawad ME, Sevick-Muraca EM. A new optical and nuclear dual-labeled imaging agent targeting interleukin 11 receptor alpha-chain. Bioconjug Chem 2007;18:397-402.
174. Zhang ZR, Liang KX, Bloch S, Berezin M, Achilefu S. Monomolecular multimodal fluorescence-radioisotope imaging agents. Bioconjug Chem 2005;16:1232-1239.
175. Yang Z, Zheng SY, Harrison WJ, Harder J, Wen XX, Gelovani JG, Qiao A, Li C. Long-circulating near-infrared fluorescence core-cross-linked polymeric micelles: Synthesis, characterization, and dual nuclear/optical imaging. Biomacromolecules 2007;8:3422-3428.
176. Cai WB, Chen K, Li ZB, Gambhir SS, Chen XY. Dual-function probe for PET and near-infrared fluorescence imaging of tumor vasculature. J Nucl Med 2007;48:1862-1870.
177. Sekine I, Shimizu C, Nishio K, Saijo N, Tamura T. A literature review of molecular markers predictive of clinical response to cytotoxic chemotherapy in patients with breast cancer. Int J Clin Oncol 2009;14:112-119.
178. Carey MP, Burish TG. Etiology and treatment of the psychological side effects associated with cancer chemotherapy: A critical review and discussion. Psychol Bull 1988;104:307-325.
179. Lemieux J, Maunsell E, Provencher L. Chemotherapy-induced alopecia and effects on quality of life among women with breast cancer: A literature review. Psycho-Oncology 2008;17:317-328.
180. Yadav S, van Vlerken LE, Little SR, Amiji MM. Evaluations of combination MDR-1 gene silencing and paclitaxel administration in biodegradable polymeric nanoparticle formulations to overcome multidrug resistance in cancer cells. Cancer Chemother Pharm 2009;63:711-722.
181. Altundag K, Dede DS, Purnak T. Albumin-bound paclitaxel (ABI-007; Abraxane) in the management of basal-like breast carcinoma. J Clin Pathol 2007;60:958.
182. Burch PA, Mailliard JA, Hillman DW, Perez EA, Krook JE, Rowland KM, Veeder MH, Cannon MW, Ingle JN. Phase II study of gemcitabine plus cisplatin in patients with metastatic breast cancer-A north central cancer treatment group trial. Am J Clin Oncol Cancer Clin Trials 2005;28:195-200.
183. Gardner ER, Dahut W, Figg WD. Quantitative determination of total and unbound paclitaxel in human plasma following Abraxane treatment. J Chromatogr B Anal Technol Biomed Life Sci 2008;862:213-218.
184. Leroux JC, Allemann E, Doelker E, Gurny R. New approach for the preparation of nanoparticles by an emulsification-diffusion method. Eur J Pharm Biopharm 1995;41:14-18.
185. Soppimath KS, Tan DCW, Yang YY. pH-triggered thermally responsive polymer core-shell nanoparticles for drug delivery. Adv Mater 2005;17:318.
186. Tang YQ, Liu SY, Armes SP, Billingham NC. Solubilization and controlled release of a hydrophobic drug using novel micelle-forming ABC triblock copolymers. Biomacromolecules 2003;4:1636-1645.
187. Forssen EA. The design and development of DaunoXome(R) for solid tumor targeting in vivo. Adv Drug Deliv Rev 1997;24:133-150.
188. Lau KG, Hattori S, Chopra S, O'Toole EA, Storey A, Nagai T, Maitani Y. Ultra-deformable liposomes containing bleomycin: In vitro stability and toxicity on human cutaneous keratinocyte cell lines. Int J Pharm 2005;300:4-12.
189. Bronich TK, Keifer PA, Shlyakhtenko LS, Kabanov AV. Polymer micelle with cross-linked ionic core. J Am Chem Soc 2005;127:8236-8237.
190. Liu XM, Pramoda KP, Yang YY, Chow SY, He CB. Cholesteryl-grafted functional amphiphilic poly(N-isopropylacrylamide-co-N-hydroxylmethylacrylamide): Synthesis, temperaturesensitivity, self-assembly and encapsulation of a hydrophobic agent. Biomaterials 2004;25:2619-2628.
191. Zhang Y, Zhuo RX. Synthesis and drug release behavior of poly (trimethylene carbonate)-poly (ethylene glycol)-poly (trimethylene carbonate) nanoparticles. Biomaterials 2005;26:2089-2094.
192. Ellena JF, Le M, Cafiso DS, Solis RM, Langston M, Sankaram MB. Distribution of phospholipids and triglycerides in multivesicular lipid particles. Drug Deliv 1999;6:97-106.
193. Gillies ER, Frechet JMJ. A new approach towards acid sensitive copolymer micelles for drug delivery. Chem Commun 2003;14:1640-1641.
194. Gillies ER, Frechet JMJ. pH-responsive copolymer assemblies for controlled release of doxorubicin. Bioconjug Chem 2005;16:361-368.
195. Lee ES, Na K, Bae YH. Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor. J Control Release 2005;103:405-418.
196. Chung JE, Yokoyama M, Okano T. Inner core segment design for drug delivery control of thermo-responsive polymeric micelles. J Control Release 2000;65:93-103.
197. Jeong B, Bae YH, Kim SW. Biodegradable thermosensitive micelles of PEG-PLGA-PEG triblock copolymers. Colloid Surface B 1999;16:185-193.
198. Gopin A, Ebner S, Attali B, Shabat D. Enzymatic activation of second-generation dendritic prodrugs: Conjugation of self-immolative dendrimers with poly(ethylene glycol) via click chemistry. Bioconjug Chem 2006;17:1432-1440.
199. Gao ZG, Fain HD, Rapoport N. Controlled and targeted tumor chemotherapy by micellar-encapsulated drug and ultrasound. J Control Release 2005;102:203-222.
200. Husseini GA, Rapoport NY, Christensen DA, Pruitt JD, Pitt WG. Kinetics of ultrasonic release of doxorubicin from pluronic P105 micelles. Colloid Surface B 2002;24:253-264.
201. Pruitt JD, Pitt WG. Sequestration and ultrasound-induced release of doxorubicin from stabilized pluronic P105 micelles. Drug Deliv 2002;9:253-258.
202. Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M, Moan J, Peng Q. Photodynamic therapy. J Natl Cancer I 1998;90:889-905.
203. Cuenca RE, Allison RR, Sibata C, Downie GH. Breast cancer with chest wall progression: Treatment with photodynamic therapy. Ann Surg Oncol 2004;11:322-327.
204. Moore CM, Pendse D, Emberton M. Photodynamic therapy for prostate cancer-A review of current status and future promise. Nat Clin Pract Urol 2009;6:18-30.
205. Awan MA, Tarin SA. Review of photodynamic therapy. Surg J R Coll Surg E 2006;4:231-236.
206. Bergstrom LC, Vucenik I, Hagen IK, Chernomorsky SA, Poretz RD. In vitro photocytotoxicity of lysosomotropic immunoliposomes containing pheophorbide a with human bladder-carcinoma cells. J Photoch Photobio B 1994;24:17-23.
207. Oku N, Saito N, Namba Y, Tsukada H, Dolphin D, Okada S. Application of long-circulating liposomes to cancer photodynamic therapy. Biol Pharm Bull 1997;20:670-673.
208. Troyan SL, Kianzad V, Gibbs-Strauss SL, Gioux S, Matsui A, Oketokoun R, Ngo L, Khamene A, Azar F, Frangioni JV. The FLARE((TM)) intraoperative near-infrared fluorescence imaging system: A first-in-human clinical trial in breast cancer sentinel lymph node mapping. Ann Surg Oncol 2009;16:2943-2952.
209. Samia ACS, Chen XB, Burda C. Semiconductor quantum dots for photodynamic therapy. J Am Chem Soc 2003;125:15736-15737.
210. Shi LX, Hernandez B, Selke M. Singlet oxygen generation from water-soluble quantum dot-organic dye nanocomposites. J Am Chem Soc 2006;128:6278-6279.
211. Tsay JM, Trzoss M, Shi LX, Kong XX, Selke M, Jung ME, Weiss S. Singlet oxygen production by peptide-coated quantum dot-photosensitizer conjugates. J Am Chem Soc 2007;129:6865-6871.
212. Cao YF, Koo YEL, Koo SM, Kopelman R. Ratiometric singlet oxygen nano-optodes and their use for monitoring photodynamic therapy nanoplatforms. Photochem Photobiol 2005;81:1489-1498.
213. Shrieve DC, Klish M, Wendland MM, Watson GA. Basic principles of radiobiology, radiotherapy, and radiosurgery. Neurosurg Clin N Am 2004;15:467.
214. Cuncins-Hearn A, Saunders C, Walsh D, Borg M, Buckingham J, Frizelle F, Maddern G. A systematic review of intraoperative radiotherapy in early breast cancer. Breast Cancer Res Tr 2004;85:271-280.
215. Koukourakis MI, Touloupidis S. External beam radiotherapy for prostate cancer: Current position and trends. Anticancer Res 2006;26:485-494.
216. Norderhaug I, Dahl O, Hoisaeter PA, Heikkila R, Klepp O, Olsen DR, Kristiansen IS, Waehre H, Johansen TEB. Brachytherapy for prostate cancer: A systematic review of clinical and cost effectiveness. Eur Urol 2003;44:40-46.
217. Shapiro B, Gross MD, Shulkin B. Radioisotope diagnosis and therapy of malignant pheochromocytoma. Trends Endocrin Met 2001;12:469-475.
218. Escorcia FE, McDevitt MR, Villa CH, Scheinberg DA. Targeted nanomaterials for radiotherapy. Nanomedicine Uk 2007;2:805-815.
219. Roa W, Zhang XJ, Guo LH, Shaw A, Hu XY, Xiong YP, Gulavita S, Patel S, Sun XJ, Chen J, Moore R, Xing JZ. Gold nanoparticle sensitize radiotherapy of prostate cancer cells by regulation of the cell cycle. Nanotechnology 2009;20:375101.
220. Cho SH. Estimation of tumour dose enhancement due to gold nanoparticles during typical radiation treatments: A preliminary Monte Carlo study. Phys Med Biol 2005;50:N163-N173.
221. Cho SH, Jones BL, Krishnan S. The dosimetric feasibility of gold nanoparticle-aided radiation therapy (GNRT) via brachytherapy using low-energy gamma-/X-ray sources. Phys Med Biol 2009;54:4889-4905.
222. Foley EA, Carter JD, Shan F, Guo T. Enhanced relaxation of nanoparticle-bound supercoiled DNA in X-ray radiation. Chem Commun 2005;25:3192-3194.
223. Hainfeld JF, Slatkin DN, Smilowitz HM. The use of gold nanoparticles to enhance radiotherapy in mice. Phys Med Biol 2004;49:N309-N315.
224. Zheng Y, Ffunting DJ, Ayotte P, Sanche L. Radiosensitization of DNA by gold nanoparticles irradiated with high-energy electrons (Vol 169, Page 19-27, 2008). Radiat Res 2008;169:481-482.
225. Chang CH, Stabin MG, Chang YJ, Chen LC, Chen MH, Chang TJ, Lee TW, Ting G. Comparative dosimetric evaluation of nanotargeted Re-188-(DXR)-liposome for internal radiotherapy. Cancer Biother Radio 2008;23:749-758.
226. Emfietzoglou D, Kostarelos K, Papakostas A, Yang WH, Ballangrud A, Song H, Sgouros G. Liposome-mediated radiotherapeutics within avascular tumor spheroids: Comparative dosimetry study for various radionuclides, liposome systems, and a targeting antibody. J Nucl Med 2005;46:89-97.
227. Emfietzoglou D, Kostarelos K, Sgouros G. An analytic dosimetry study for the use of radionuclide-liposome conjugates in internal radiotherapy. J Nucl Med 2001;42:499-504.
228. Henriksen G, Schoultz BW, Michaelsen TE, Bruland OS, Larsen RH. Sterically stabilized liposomes as a carrier for alpha-emitting radium and actinium radionuclides. Nucl Med Biol 2004;31:441-449.
229. Kostarelos K, Emfietzoglou D. Tissue dosimetry of liposome-radionuclide complexes for internal radiotherapy: Toward liposome-targeted therapeutic radiopharmaceuticals. Anticancer Res 2000;20:3339-3345.
230. Syme AM, McQuarrie SA, Middleton JW, Fallone BG. Dosimetric model for intraperitoneal targeted liposomal radioimmunotherapy of ovarian cancer micrometastases. Phys Med Biol 2003;48:1305-1320.